3.5.9. summary evidence recommendations safety monitoring testosterone treatment. summary evidenceletestosterone therapy contraindicated men secondary hypogonadism desire fertility.1atestosterone therapy contraindicated men active prostate cancer breast cancer, patients usually excluded rcts.1atestosterone therapy increase risk prostate cancer, long-term prospective follow-up data required validate statement.1athe effect testosterone therapy men severe lower-urinary tract symptoms limited, patients usually excluded rcts.1athere substantive evidence testosterone therapy, replaced normal levels, results development major adverse cardiovascular events.1athere evidence relationship testosterone therapy mild, moderate cpap-treated severe sleep apnoea.1b recommendationsstrength ratingfully counsel symptomatic hypogonadal men surgically treated localised prostate cancer (pca) currently without evidence active disease considering testosterone therapy, emphasising lack sufficient safety data long-term follow-up.weakrestrict treatment patients low risk recurrent pca*. treatment start least one year follow-up prostate-specific antigen (psa) level < 0.01 ng/ml.weakadvise patients safety data use testosterone therapy men treated breast cancer unknown.strongassess cardiovascular risk factors commencing testosterone therapy.strongassess men known cardiovascular disease (cvd) cardiovascular symptoms initiating testosterone therapy monitor men close clinical assessment evaluation treatment.strongtreat men hypogonadism pre-existing cvd, venous-thromboembolism chronic cardiac failure, require testosterone therapy caution, careful clinical monitoring regular measurement haematocrit (not exceeding 54%) testosterone levels.weakexclude family history venous-thromboembolism starting testosterone therapy.strongmonitor testosterone, haematocrit three, six twelve months testosterone therapy initiation, thereafter annually. haematocrit > 54% requires testosterone therapy adjustment withdrawal venesection required. re-introduce testosterone therapy lower dose haematocrit normalised consider switching topical testosterone preparations.strongevaluate patients polycythaemia vera higher risk developing elevated haematocrit every three months first year testosterone therapy, least every six months thereafter.strongevaluate total psa pca survivors three, six twelve months first year testosterone therapy, annually thereafter.strong *as eau risk groups biochemical recurrence localised locally advanced prostate cancer(see eau prostate cancer guidelines, 2024)